ACADIA Pharmaceuticals Inc. (ACAD) Income Statement
ACAD 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsACAD revenue and net income
Where ACAD's revenue goes
2025Each bar shows an amount and its share of revenue. ACAD kept 36.5% of revenue as net income.
ACAD profit margins
ACAD growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +11.9% | +27.5% | +19.4% | +165.7% |
| Gross profit | +12.2% | +24.7% | +18.5% | +163.5% |
| Operating income | −54.6% | — | — | — |
| Net income | +72.7% | — | — | — |
| EPS (diluted) | −50.7% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ACAD quarterly EPS vs estimates
ACADIA Pharmaceuticals beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 4, 2026 (estimate $0.21).
ACAD income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.07B | $957.8M | $726.4M | $517.2M | $484.1M | $441.8M | $339.1M | $223.8M | $124.9M | $17.3M |
| Cost of revenue | $89.0M | $81.8M | $45.7M | $10.2M | $19.1M | $20.6M | $19.6M | $18.3M | $13.1M | $4.4M |
| Gross profit | $982.5M | $876.0M | $680.7M | $507.1M | $465.0M | $421.2M | $319.5M | $205.5M | $111.8M | $12.9M |
| Research & development | $328.8M | $303.2M | $351.6M | $361.6M | $239.4M | $319.1M | $240.4M | $187.2M | $149.2M | $99.3M |
| Sales, general & admin | $548.9M | $488.4M | $402.5M | $374.6M | $396.0M | $388.7M | $325.6M | $265.8M | $255.1M | $188.1M |
| Total operating expenses | $877.7M | $645.2M | $754.1M | $730.7M | $635.4M | $707.8M | $566.0M | $452.9M | $404.3M | $285.7M |
| Operating income | $104.8M | $230.8M | −$73.4M | −$223.6M | −$170.4M | −$286.6M | −$246.5M | −$247.4M | −$292.4M | −$272.8M |
| Interest income | $31.7M | $25.5M | $17.2M | $6.6M | $591,000 | $6.6M | $11.2M | $5.3M | $4.1M | $2.8M |
| Interest expense | — | — | — | $6.6M | $6.3M | $8.5M | $14.9M | $0 | $0 | $0 |
| Income before taxes | $138.9M | $258.1M | −$51.0M | −$213.4M | −$167.5M | −$281.0M | −$234.4M | −$243.9M | −$288.3M | −$270.1M |
| Income taxes | −$252.1M | $31.6M | $10.2M | $2.5M | $351,000 | $611,000 | $876,000 | $1.3M | $1.1M | $1.3M |
| Net income | $391.0M | $226.5M | −$61.3M | −$216.0M | −$167.9M | −$281.6M | −$235.3M | −$245.2M | −$289.4M | −$271.4M |
| EBITDA | $150.7M | $100.2M | −$45.5M | −$221.6M | −$167.1M | −$283.7M | −$243.8M | −$244.4M | −$289.7M | −$271.0M |
| EPS (diluted) | $0.67 | $1.36 | −$0.38 | −$1.34 | −$1.05 | −$1.80 | −$1.60 | −$1.95 | −$2.35 | −$2.34 |
| Gross margin | 91.7% | 91.5% | 93.7% | 98.0% | 96.0% | 95.3% | 94.2% | 91.8% | 89.5% | 74.6% |
| Operating margin | 9.8% | 24.1% | −10.1% | −43.2% | −35.2% | −64.9% | −72.7% | −110.6% | −234.1% | −1,574.1% |
| Net margin | 36.5% | 23.6% | −8.4% | −41.8% | −34.7% | −63.7% | −69.4% | −109.6% | −231.7% | −1,565.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $308.0M | $268.1M | $284.0M | $278.6M | $264.6M | $244.3M | $259.6M | $250.4M | $242.0M | $205.8M | $231.0M | $211.7M |
| Cost of revenue | $28.3M | $24.8M | $26.2M | $21.6M | $20.7M | $20.4M | $21.8M | $18.9M | $18.2M | $23.0M | $17.9M | $14.6M |
| Gross profit | $279.6M | $243.3M | $257.8M | $257.0M | $243.8M | $223.9M | $237.8M | $231.5M | $223.7M | $182.9M | $213.2M | $197.1M |
| Research & development | $81.6M | $76.9M | $84.8M | $87.8M | $78.0M | $78.3M | $100.7M | $66.6M | $76.2M | $59.7M | $66.7M | $157.0M |
| Sales, general & admin | $160.3M | $171.0M | $155.6M | $133.4M | $133.5M | $126.4M | $130.1M | $133.3M | $117.1M | $108.0M | $111.5M | $97.9M |
| Total operating expenses | $241.8M | $247.9M | $240.4M | $221.2M | $211.5M | $204.6M | $84.3M | $199.9M | $193.3M | $167.7M | $178.2M | $254.9M |
| Operating income | $37.8M | −$4.6M | $17.4M | $35.8M | $32.4M | $19.3M | $153.5M | $31.6M | $30.4M | $15.2M | $34.9M | −$57.8M |
| Interest income | $8.0M | $8.1M | $8.3M | $8.2M | $7.2M | $7.9M | $7.0M | $6.6M | $6.4M | $5.5M | $4.8M | $4.1M |
| Income before taxes | $46.5M | $4.0M | $26.3M | $44.6M | $40.2M | $27.8M | $161.1M | $38.8M | $37.2M | $21.0M | $39.7M | −$52.1M |
| Income taxes | $15.0M | $344,000 | −$247.2M | −$27.2M | $13.5M | $8.8M | $17.3M | $6.0M | $3.8M | $4.4M | −$6.1M | $13.0M |
| Net income | $31.5M | $3.6M | $273.6M | $71.8M | $26.7M | $19.0M | $143.7M | $32.8M | $33.4M | $16.6M | $45.8M | −$65.2M |
| EBITDA | $32.4M | $7.0M | $29.2M | $47.5M | $43.1M | $30.7M | $12.2M | $41.4M | $39.8M | $26.5M | $41.3M | −$50.4M |
| EPS (diluted) | $0.18 | $0.02 | $0.14 | $0.26 | $0.16 | $0.11 | $0.86 | $0.20 | $0.20 | $0.10 | $0.28 | −$0.40 |
| Gross margin | 90.8% | 90.8% | 90.8% | 92.2% | 92.2% | 91.7% | 91.6% | 92.5% | 92.5% | 88.8% | 92.3% | 93.1% |
| Operating margin | 12.3% | −1.7% | 6.1% | 12.8% | 12.2% | 7.9% | 59.1% | 12.6% | 12.6% | 7.4% | 15.1% | −27.3% |
| Net margin | 10.2% | 1.4% | 96.3% | 25.8% | 10.1% | 7.8% | 55.4% | 13.1% | 13.8% | 8.0% | 19.8% | −30.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ACAD's financial statements (latest annual report filed February 25, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ACAD financial results
In fiscal year 2025 (ended December 31, 2025), ACADIA Pharmaceuticals reported revenue of $1.1 billion, up 11.9% from the year before. It had net income of $391.0 million (up 72.7%), a net profit margin of 36.5%. Diluted earnings per share came to $0.67. Over five years revenue grew at an average rate of 19.4% a year.
See the ACAD stock overview for the latest quote and news, or the ACAD chart for price history and technical indicators.
ACAD income statement FAQ
What is ACADIA Pharmaceuticals's annual revenue?
ACADIA Pharmaceuticals reported total revenue of $1.1 billion for fiscal year 2025, which ended on December 31, 2025. That was up 11.9% from $957.8 million the previous year.
Is ACADIA Pharmaceuticals profitable?
Yes. ACADIA Pharmaceuticals reported net income of $391.0 million in fiscal 2025, a net profit margin of 36.5%; its operating margin was 9.8%.
What is ACADIA Pharmaceuticals's gross margin?
ACADIA Pharmaceuticals's gross margin was 91.7% in fiscal 2025: for every $100 of revenue, ACADIA Pharmaceuticals kept $92 after the direct cost of its products and services.
How much does ACADIA Pharmaceuticals spend on research and development?
ACADIA Pharmaceuticals spent $328.8 million on research and development in fiscal 2025, 30.7% of revenue.
How fast is ACADIA Pharmaceuticals growing?
Revenue grew 19.4% a year on average over the last five fiscal years, from $441.8 million to $1.1 billion.
What are ACADIA Pharmaceuticals's earnings per share?
ACADIA Pharmaceuticals earned $0.67 per diluted share in fiscal 2025, compared with $1.36 a year earlier.
When will ACADIA Pharmaceuticals report its next earnings?
ACADIA Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes.
When does ACADIA Pharmaceuticals's fiscal year end?
ACADIA Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 25, 2026.